- Home
- CELC vs PROK Comparison
CELC vs PROK Comparison
Compare CELC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- PROK
- Stock Information
- Founded
- CELC 2011
- PROK 2015
- Country
- CELC United States
- PROK United States
- Employees
- CELC N/A
- PROK N/A
- Industry
- CELC Medical Specialities
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CELC Health Care
- PROK Health Care
- Exchange
- CELC Nasdaq
- PROK Nasdaq
- Market Cap
- CELC 440.0M
- PROK 384.2M
- IPO Year
- CELC 2017
- PROK N/A
- Fundamental
- Price
- CELC $51.79
- PROK $2.36
- Analyst Decision
- CELC Strong Buy
- PROK Buy
- Analyst Count
- CELC 6
- PROK 5
- Target Price
- CELC $46.50
- PROK $6.25
- AVG Volume (30 Days)
- CELC 2.9M
- PROK 3.1M
- Earning Date
- CELC 08-14-2025
- PROK 08-12-2025
- Dividend Yield
- CELC N/A
- PROK N/A
- EPS Growth
- CELC N/A
- PROK N/A
- EPS
- CELC N/A
- PROK N/A
- Revenue
- CELC N/A
- PROK $527,000.00
- Revenue This Year
- CELC N/A
- PROK $105.79
- Revenue Next Year
- CELC N/A
- PROK N/A
- P/E Ratio
- CELC N/A
- PROK N/A
- Revenue Growth
- CELC N/A
- PROK N/A
- 52 Week Low
- CELC $7.58
- PROK $0.46
- 52 Week High
- CELC $53.70
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- CELC 92.18
- PROK 45.54
- Support Level
- CELC $38.00
- PROK $2.15
- Resistance Level
- CELC $53.40
- PROK $2.46
- Average True Range (ATR)
- CELC 3.33
- PROK 0.34
- MACD
- CELC 0.92
- PROK -0.13
- Stochastic Oscillator
- CELC 89.44
- PROK 15.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.